Trials / Completed
CompletedNCT01511640
Behavioral Effects of Pregabalin and Cannabis
Behavioral Effects of Drugs (Outpatient)(43)
- Status
- Completed
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Joshua A. Lile, Ph.D. · Academic / Other
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
Cannabis is the most commonly used illicit drug in the United States, and its use is associated with rates of development of abuse and dependence, treatment admission and relapse that are comparable to other illicit drugs. Currently there is no effective pharmacological treatment for cannabis-use disorders. The purpose of the present study is to evaluate the ability of pregabalin to reduce cannabis use thereby evaluating its effectiveness as a medication for cannabis-use disorders.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pregabalin | pregabalin 2x daily for duration of study |
| DRUG | Placebo | placebo 2x daily for duration of study |
Timeline
- Start date
- 2017-02-01
- Primary completion
- 2020-03-15
- Completion
- 2020-03-15
- First posted
- 2012-01-18
- Last updated
- 2021-09-10
- Results posted
- 2021-09-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01511640. Inclusion in this directory is not an endorsement.